29 April 2025NewsEuropeSarah Speight

AstraZeneca to appeal invalidated diabetes patent in generics dispute

EWHC ruling discusses application of EPO case law regarding lack of plausibility and lack of technical contribution | Court had earlier overturned a first-instance decision allowing an injunction against Glenmark’s diabetes generic | AstraZeneca intends to appeal.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

How pharma should prep for the six-bill avalanche from Congress

17 April 2025 The bipartisan legislative push could create big hurdles for drug development, with concerns mounting over limited patent protections and increased litigation risks, hears Marisa Woutersen.

Big Pharma

AstraZeneca fends off diabetes generic, for now

10 April 2025 Decision overturns earlier decision allowing generic drug maker to launch version | Dispute centres on $300-million dollar treatment for diabetes, chronic heart failure and kidney disease—currently protected by a challenged SPC.

Americas

Patent cliff: 5 blockbusters running out of road

1 April 2025 MSD, Novartis and Eli Lilly are among those whose multi-billion-dollar patents are hurtling towards expiration, writes Marisa Woutersen.